Liver Disorders
Read Time: 4 mins

The Global Liver Institute “Liver Health is Public Health” Initiative

Copy Link
Published Online: Jun 16th 2023 touchREVIEWS in Endocrinology. 2023;19(2):2-3 DOI:
Authors: Donna R Cryer
Quick Links:
Article Information

Donna R Cryer
Donna R Cryer, JD, is Founder and Chief Executive Officer of the Global Liver Institute (GLI). The GLI is a premier patient-driven liver health nonprofit organization, with offices and partnerships across five continents. Moved by her own experience with receiving a liver transplant at the age of 28, Mrs Cryer serves as a fierce advocate for the transformative potential of patient engagement in health policy, research, data and system design. Her expertise and effectiveness in advancing the voices of patients in defining and designing equitable healthcare has been recognized by the United States Congress and the White House. In 2021, Mrs Cryer received both the Global Genes RARE Champions of Hope Founder’s Award and the American Association for the Study of the Liver Distinguished Advocacy Service Award. Mrs Cryer serves on the Boards of Directors for the Council of Medical Specialty Societies, Sibley Memorial Hospital/Johns Hopkins Medicine and the Color of Crohns and Chronic Illness. She was the first patient to serve on the American Board of Internal Medicine Gastroenterology Specialty Board. Mrs Cryer received an undergraduate degree from Harvard and a Juris Doctorate from the Georgetown University Law Center.


Liver, liver diseases, liver health, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, public health, public health initiative


Liver conditions are often misunderstood, mischaracterized and stigmatized, which results in under-diagnosis, under-treatment and unnecessarily poor outcomes worldwide. The Global Liver Institute (GLI) “Liver Health is Public Health” initiative aims to respond to this unmet need and educate the public about liver health and disease prevention. In this expert interview, Donna Cryer discusses the misconceptions that persist around liver conditions, how these can be overcome, as well as how the “Liver Health is Public Health” initiative aims to address on-going challenges to shift the conversation on liver health.

Q. How does the Global Liver Institute help support patients and endocrinologists?

GLI’s mission is to improve the lives of individuals and families impacted by liver disease through promoting innovation, encouraging collaboration and scaling optimal approaches to help eradicate liver diseases. Many liver diseases, particularly nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis, are frequently associated with diabetes and other metabolic disorders. Thus, endocrinologists need to be aware and up to date on the latest guidelines, clinical pathways and barriers that patients face when receiving care. GLI has consistently partnered with leading endocrinologists and endocrine organizations, such as the American Association of Clinical Endocrinology and the Endocrine Society, to co-create educational material and align agendas.

GLI helps patients by supporting their endocrinologists while empowering patients to advocate for themselves, and others in the clinic and their communities. GLI also supports patients in front of policymakers via training and opportunities through the Advanced Advocacy Academy (A3)1 as well as joint advocacy with our Liver Action Network.2

Q. What are the aims of the “Liver Health is Public Health” initiative?

Every human body has a liver, therefore, all individuals should be informed and equipped to take action to promote liver health. GLI’s “Liver Health is Public Health” initiative is a direct response to the fact that liver conditions are stigmatized and misunderstood, which results in under-diagnosis, under-treatment and unnecessarily poor outcomes worldwide.3 To counter this, we will need to broaden the circle of activists and organizations engaged in liver health activities, align with successful public health efforts and leverage all public health tools; that is, food policy, environmental policy, behavioural science, as well as drug, device, and diagnostic innovation.

Q. What activities and resources will be available as part of the “Liver Health is Public Health” initiative?

In GLI’s mission to elevate liver health to its rightful place on the global public health agenda, the initiative will educate community members, healthcare providers and policymakers about liver health and disease prevention. The initiative will pave the way for best practices that account for differences in: stage of disease, patient preferences, values, culture, language, geography and socioeconomic environment.

During 2022, its pilot year, the initiative launched two valuable resources: a series of educational brochures about liver health and the Global State of Liver Health report.4

The first resource launched was the Liver Health Basics booklet, which provides a foundation for understanding liver health.5 It covers the function of the liver, common symptoms and types of liver diseases, drivers of liver disease (including diabetes and related conditions) and outlines positive liver habits. Specialists, such as endocrinologists, are encouraged to share this booklet with their patients, to encourage a baseline understanding of liver health. This is the first in a series of educational brochures targeting different audiences including patients, caregivers, primary care providers, non-hepatology specialists and more.

The Global State of Liver Health report defines and analyses the landscape of liver health worldwide.6 It draws from available epidemiological studies and the perspectives of locally based experts, such as hepatologists, gastroenterologists, endocrinologists, liver patient advocates and disease control programmes. The report is both a foundational resource and a rallying cry for clinicians, policymakers, patient advocates and other community leaders to fight liver disease.

In 2023, GLI is developing further pieces of educational resources for the general public, policymakers, payers and provider audiences. Our team is expanding and updating the Global State of Liver Health report with deep dives into additional countries.

Q. What misconceptions persist around liver conditions and how can these be overcome?

One of the most common misconceptions related to liver diseases is that they are instantly associated with alcohol or drug use. However, obesity is another driving cause of liver disease, which is unfortunately another condition that carries stigma.

It is still believed that patients with diabetes are not susceptible to liver disease, even though a strong, bidirectional relationship exists between the two conditions. Around 70% of people with type 2 diabetes have NAFLD, and the prevalence of diabetes among people with NAFLD is 2.5 times higher than in the general population.7,8

GLI are committed to on-going, transparent conversations about liver health that deconstruct the stigma around liver diseases and ensure the needs of patients with liver diseases are heard and accounted for.

Q. How will this programme address on-going challenges, and shift the conversation on liver health?

It is critical for every single individual to recognize the liver, learn more about it and know how to keep it functioning well. Many know the function of the heart, lungs, brain or stomach, yet many would have difficulties explaining what the liver does. The “Liver Health is Public Health” initiative will simultaneously boost public understanding of the liver and encourage health experts across the breadth of specialities to join the discussion in order to collectively shift global attention.

Q. How can people get involved?

We invite everyone to get involved. This includes doctors who are caring for patients as well as participating in seminars and panels to share the latest updates in the field. We also invite scientific societies worldwide to endorse the initiative, as well as partnering organizations hosting awareness and educational events, and individuals who are eager to learn about the liver and share vital information. Eventually, we hope that policymakers can join the conversation and take part in prioritizing liver health as a key component in the public health agenda.

You can learn more at:

Article Information:

Donna R Cryer has no financial or non-financial relationships or activities to declare in relation to this article.

Compliance With Ethics

This article is an opinion piece and does not report on new clinical data, or any studies with human or animal subjects performed by the author.

Review Process

This is an expert interview and as such has not undergone the journal’s standard peer review process.


The named author meets the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, takes responsibility for the integrity of the work as a whole, and has given final approval for the version to be published.


Donna R Cryer12973 SW 112th St.Miami, FL. 33186Box:


No funding was received in the publication of this article.


This article is freely accessible at ©Touch Medical Media 2023


Medical writing support was provided by Touch Medical Media and funded by Touch Medical Media.

Data Availability

Data sharing is not applicable to this article as no datasets were generated or analysed during the writing of this article.




1. Global Liver InstituteAdvanced advocacy academy2023Available (Date last accessed23 April 2023).

2. Global Liver InstituteLiver action network2023Available (Date last accessed1 June 2023).

3. Global Liver InstituteLiver health is public health2023Available (Date last accessed23 April 2023)

4. Global Liver InstituteInitiative resources2023Available (Date last accessed23 April 2023)

5. Global Liver InstituteLiver Health Basics BookletWashington DCGlobal Liver Institute2022.

6. Global Liver InstituteGlobal State of Liver Health ReportWashington DCGlobal Liver Institute, 2022.

7. Targher GBertolini LPadovani Ret alPrevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patientsDiabetes Care. 2007;30:12128. DOI10.2337/dc06-2247

8. Khandelwal RDassanayake ASConjeevaram HSSingh SPNon-alcoholic fatty liver disease in diabetes: When to refer to the hepatologist? World J Diabetes. 2021;12:147993. DOI: 10.4239/wjd.v12.i9.1479

Further Resources

Share this Article
Related Content In Liver Disorders
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72